PBH
Prestige Consumer Healthcare Inc.61.60
-0.26-0.42%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
3.03BP/E (TTM)
15.25Basic EPS (TTM)
4.04Dividend Yield
0%Recent Filings
8-K
10-Q
10-Q
Q1 FY2026 results
Prestige Consumer Healthcare's Q1 FY2026 revenues fell 6.6% y/y to $249.5M, driven by supply shortages in Eye & Ear Care that slashed sales 35.9% y/y, yet gross margins expanded to 56.2% from 54.7% on better product mix and lower air freight. Operating income held steady at $71.8M, while net income dipped 3.2% y/y to $47.5M with diluted EPS of $0.95 on 49.8M shares—consistent with no material anti-dilution. Cash swelled to $139.5M after $79.0M operating cash flow and $1.9M capex for $77.1M free cash flow (derived), funding $34.8M share repurchases amid $1.0B fixed-rate debt and $173.2M revolver availability. The pending $100M acquisition of Pillar5 Pharma eyes bolstering eye care capacity, closing Q3 FY2026. Supply chain disruptions linger as a key risk.
8-K
Acquires Pillar5 to boost eye care supply
Prestige Consumer Healthcare agreed to buy Pillar5 Pharma, its Clear Eyes supplier, for CAD 150 million in cash on August 4, 2025, aiming to fix supply shortages that hammered Q1 revenue down 6.6% to $249.5 million. The deal, set to close in Q3 fiscal 2026, should secure long-term eye care capacity while staying neutral to EPS. Supply woes persist into H1, but 2H improvements loom. Risks hinge on meeting closing conditions.
10-K
FY2025 results
Prestige Consumer Healthcare delivered steady FY2025 results, with total revenues edging up 1.1% year-over-year to $1.14 billion, driven by a 6.4% surge in the International OTC Healthcare segment that offset flat North American performance; gastrointestinal products fueled the international momentum, while cough & cold sales dipped 11.8% domestically amid supply constraints. Q4 wrapped the year on a resilient note, with gross margins expanding to 55.8% from 55.5% thanks to lower freight costs and favorable product mix, though non-strategic brand impairments of $12.5 million tempered operating income to $336.8 million. Contribution margins held firm at 42.1%, bolstered by disciplined marketing spend. The company strengthened its liquidity posture, repaying the full $135 million term loan and advancing $51.5 million in share buybacks under its $300 million program, leaving $248 million available. No formal FY2026 guidance was issued, but management eyes continued international growth. Supply chain disruptions, especially in eye care, remain a key risk that could stall quarterly momentum.
IPO
Employees
Sector
Industry
BHC
Bausch Health Companies Inc.
6.93+0.02
COTY
Coty Inc.
3.27-0.01
HIMS
Hims & Hers Health, Inc.
36.86+0.61
HLN
Haleon plc
9.85+0.02
KVUE
Kenvue Inc.
17.25+0.04
PAHC
Phibro Animal Health Corporatio
40.40-0.27
PFE
Pfizer, Inc.
25.53-0.90
PRGO
Perrigo Company plc
13.02+0.18
SNYR
Synergy CHC Corp.
1.85-0.11
VTRS
Viatris Inc.
11.46-0.20